Hemagen Diagnostics Inc (HMGN)

Currency in USD
0.000
0.000(0.00%)
Delayed Data·

HMGN Financial Summary

Key Ratios

P/E Ratio-0
Price/Book-0
Debt / Equity-141.33%
Return on Equity29.06%
Dividend Yield0.00%
EBITDA-273.66K
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2003
30/09
2004
30/09
2005
30/09
2006
30/09
2007
30/09
2008
30/09
2009
30/09
2010
30/09
2011
30/09
2012
30/09
* In Millions of USD (except for per share items)

Earnings

Latest Release
Feb 11, 2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
875.91K / --
EPS Revisions
Last 90 days

FAQ

What were Hemagen Diagnostics's earnings for the latest quarter?

The Hemagen Diagnostics EPS (TTM) is -0.06. Hemagen Diagnostics reported sales of 0.88, net income of -0.16, and EPS of -0.01 for the latest quarter.

What was Hemagen Diagnostics's net income for the latest quarter?

Hemagen Diagnostics's net income for the latest quarter was -0.16.

How did Hemagen Diagnostics's performance compare year-over-year in the latest quarter?

The company's revenue moved from 0.95 in the previous quarter to 0.88 in the latest quarter, and net income moved from -0.13 to -0.16 compared to the previous quarter.

What is Hemagen Diagnostics's net profit margin on a TTM basis?

Hemagen Diagnostics's trailing twelve months (TTM) net profit margin is -22.45%.

How does Hemagen Diagnostics's debt to equity ratio compare to industry standards?

Hemagen Diagnostics's total debt-to-equity ratio is -141.33%.

What is Hemagen Diagnostics's return on investment on a TTM basis?

Hemagen Diagnostics's trailing twelve months (TTM) return on investment (ROI) is 29.06%.

Did Hemagen Diagnostics gain or lose cash last quarter?

In the latest quarter, Hemagen Diagnostics's net change in cash was -0.04 million.

What were Hemagen Diagnostics's total assets and liabilities in the latest quarter?

As of the latest quarter, Hemagen Diagnostics reported total assets of 2.44 million and total liabilities of 1.95 million.

How has Hemagen Diagnostics's total revenue grown this year?

Hemagen Diagnostics's total revenue was 0.95 in the previous quarter and 0.88 in the latest quarter.

What was Hemagen Diagnostics's revenue per share for the latest quarter?

Hemagen Diagnostics's revenue per share for the latest quarter was 31.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.